丽珠医药(01513)产品纳入国家医保目录

Core Viewpoint - The announcement by the company regarding the inclusion of 194 products in the National Medical Insurance Directory for 2025, which is a significant development for its product portfolio [1] Group 1: Product Inclusion - A total of 194 products from the company have been included in the National Medical Insurance Directory for 2025, consisting of 92 Class A and 102 Class B products [1] - The injectable Aripiprazole microspheres have been included in the National Medical Insurance Directory for the first time through negotiations [1] - The injectable Triptorelin acetate microspheres have a newly added indication, while the injectable Esomeprazole sodium has successfully renewed its contract [1]